@ThePCCTC #clinicaltrials span the entire prostate cancer disease continuum and are strategically aligned with our… https://t.co/b3Q5djnGkE
Expertise
Our Investigators
Internationally recognized leaders in the field, PCCTC investigators come from the nation’s top academic medical centers where they are actively engaged in innovative, multidisciplinary prostate cancer research. Leveraging their unique insights into the underlying biology of the disease, our investigators developed the universally adopted clinical states model of prostate cancer and initiated one of the first efforts in oncology to prospectively validate endpoints proposed in definitive phase III trials, PCWG2. The individual research objectives of our investigators are well represented in our clinical trial portfolio and unified by our translational, team-based approach to drug and biomarker development.
Drug Development
The PCCTC selects and prioritizes clinical development opportunities based on our investigators’ unparalleled understanding of the global clinical trials landscape, the strength of the underlying science, and the potential to address critical unmet needs across prostate cancer’s clinical spectrum. Our studies are characterized by close interaction between basic scientists and clinical investigators to optimize the flow of promising agents into early-phase studies, and the complimentary development of novel trial designs, endpoints and predictive biomarkers which ensure the decision to advance or to discontinue a program is made objectively and rapidly. The PCCTC’s Management Team and Scientific Oversight Committee work together to address the scientific, legal, regulatory, database, budgetary, and management concerns of every trial to further accelerate the development of successful drug candidates.
Biomarker Development
A cornerstone of the PCCTC’s research strategy is the co-development of therapies and biomarkers. To transform the clinical management of prostate cancer in the near term, it is essential to develop drugs in more precisely defined and biologically relevant patient groups. The ability to screen for patients most likely to respond to a novel agent is essential for both shortening development timelines and reducing exposure to unnecessary toxicity from ineffective treatment. Following the FDA’s Critical Path Initiative, we initiated one of the first endeavors in oncology to define blood and imaging-based biomarkers, develop analytically valid assays for them, and subsequently design and conduct the dedicated clinical trials necessary to establish their clinical validity. Capitalizing on the intellectual synergy of our investigators, our extensive clinical trial portfolio, and our many resources and basic science collaborations, our long-term objective is to establish intermediate or surrogate endpoints which can predict clinical benefit and form the basis for accelerated drug approvals.
Recent News +++
Dr. Dana Rathkopf Discusses IRONMAN Registry with UroToday
Media Relations by PCCTC February 12, 2020IRONMAN – An International Registry for Men with Advanced Prostate Cancer.
Learn MorePCCTC Investigators Author Key Paper on Liquid Biopsy Data
Media Relations by PCCTC February 4, 2020Effort organized by BloodPAC describes minimum technical data elements for liquid biopsy d...
Learn MoreProstate Cancer ABCs Presents Patient and Caregiver Conference
Media Relations by PCCTC January 23, 2020Free event featuring PCCTC advocates Jan Manarite and Joel Nowak will take place Saturday,...
Learn MoreMetacure Trial: Can We Cure More Oligometastatic Prostate Cancer?
Press Releases by Cleveland Clinic January 14, 2020Study combines hormonal therapy with prostatectomy and radiation therapy of bone lesions
Learn MorePhase I DSTP3086S Trial Results Published
Media Relations by PCCTC November 11, 2019PCCTC study demonstrates safety and antitumor activity of humanized immunoglobulin G1 anti...
Learn MorePCCTC Investigators Drs. Rathkopf and McBride Receive Prestigious SU2C Grant
Press Releases by PCCTC October 17, 2019Award will fund novel trial using immunotherapy combined with radiation and hormone therap...
Learn MoreFollow Us
Dr. Graff had a critical role in bringing this important study to the @ThePCCTC https://t.co/haF9SrxpmW
Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…
2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers
careers.mskcc.org
Committed to world-class science!
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.